Dachaigh › Lymphoma › Texas › Houston
Sgrùdaidhean clionaigeach Lymphoma ann an Houston, TX
Tha 34 sgrùdaidhean airson Lymphoma a’ lorg phàirtichean aig làraichean ann agus timcheall air Houston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
A’ fastadhÌre 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A’ fastadhSgrùdadh amharc
- Texas Children's Hospital, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
A’ fastadhÌre 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A’ fastadhÌre 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
A’ fastadhÌre 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
A’ fastadhÌre 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A’ fastadhÌre 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
A’ fastadhÌre 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A’ fastadhÌre 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A’ fastadhÌre 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
A’ fastadhÌre 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A’ fastadhÌre 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A’ fastadhÌre 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
A’ fastadhÌre 1
- The University of Texas M D Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
A’ fastadhÌre 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
A’ fastadhÌre 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
A’ fastadhÌre 1/2
- Dren Investigational Site, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
A’ fastadh
- MD Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
A’ fastadhSgrùdadh amharc
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
A’ fastadhSgrùdadh amharc
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A’ fastadhÌre 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
A’ fastadhÌre 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Sgrùdaidhean Lymphoma ann am bailtean eile
- Boston, MA33 sgrùdaidhean
- New York City, NY33 sgrùdaidhean
- Washington, DC23 sgrùdaidhean
- Baldwin Park, CA21 sgrùdaidhean
- Chicago, IL20 sgrùdaidhean
- Durham, NC17 sgrùdaidhean
- St. Louis, MO15 sgrùdaidhean
- Philadelphia, PA15 sgrùdaidhean
- Cleveland, OH14 sgrùdaidhean
- Edison, NJ12 sgrùdaidhean
- Atlanta, GA12 sgrùdaidhean
- Seattle, WA12 sgrùdaidhean
Sgrùdaidhean eile ann an Houston
- Aillse Sgamhain Neo-chealla-beag145 sgrùdaidhean
- Aillse a' bhroilleach126 sgrùdaidhean
- Aillse (gach seòrsa)121 sgrùdaidhean
- Ailse metastatach104 sgrùdaidhean
- Aillse colorectal102 sgrùdaidhean
- Cancer Ovarian89 sgrùdaidhean
- Leukemia myeloid geur85 sgrùdaidhean
- Ailseachadh nan Sgamhan78 sgrùdaidhean
- Aillse Prostata76 sgrùdaidhean
- Ailse Endometrial68 sgrùdaidhean
- Cancer Pancreatic61 sgrùdaidhean
- Melanoma59 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.